Cantor Fitzgerald Has Negative View of VKTX FY2025 Earnings

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Research analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for Viking Therapeutics in a report issued on Thursday, July 24th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the biotechnology company will earn ($2.72) per share for the year, down from their prior estimate of ($2.57). Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share. Cantor Fitzgerald also issued estimates for Viking Therapeutics’ FY2026 earnings at ($4.35) EPS.

Other research analysts have also recently issued research reports about the stock. The Goldman Sachs Group assumed coverage on shares of Viking Therapeutics in a report on Tuesday, April 8th. They issued a “neutral” rating and a $30.00 target price for the company. Morgan Stanley dropped their target price on shares of Viking Therapeutics from $105.00 to $102.00 and set an “overweight” rating for the company in a report on Thursday, April 24th. Citigroup increased their target price on shares of Viking Therapeutics from $31.00 to $38.00 and gave the stock a “neutral” rating in a report on Thursday, July 24th. Truist Financial reissued a “buy” rating and issued a $75.00 target price (down previously from $95.00) on shares of Viking Therapeutics in a report on Monday, April 28th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $102.00 price objective on shares of Viking Therapeutics in a research note on Wednesday, June 25th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $86.92.

Viking Therapeutics Trading Down 0.9%

VKTX stock opened at $32.91 on Monday. The stock has a market capitalization of $3.70 billion, a P/E ratio of -21.51 and a beta of 0.62. Viking Therapeutics has a 12 month low of $18.92 and a 12 month high of $81.73. The firm has a 50-day moving average price of $28.72 and a 200-day moving average price of $28.57.

Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Wednesday, July 23rd. The biotechnology company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.14). The business’s revenue for the quarter was up NaN% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.20) EPS.

Insider Buying and Selling at Viking Therapeutics

In other Viking Therapeutics news, CFO Greg Zante sold 4,266 shares of the stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $27.76, for a total transaction of $118,424.16. Following the completion of the sale, the chief financial officer owned 168,660 shares of the company’s stock, valued at approximately $4,682,001.60. This represents a 2.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Brian Lian sold 26,889 shares of the stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $27.80, for a total transaction of $747,514.20. Following the sale, the chief executive officer directly owned 2,388,014 shares of the company’s stock, valued at $66,386,789.20. This represents a 1.11% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 35,421 shares of company stock valued at $984,405. 4.10% of the stock is currently owned by company insiders.

Institutional Trading of Viking Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. increased its position in Viking Therapeutics by 121.5% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 29,721 shares of the biotechnology company’s stock valued at $718,000 after purchasing an additional 16,302 shares during the period. GAMMA Investing LLC increased its position in Viking Therapeutics by 9,209.9% during the 1st quarter. GAMMA Investing LLC now owns 24,392 shares of the biotechnology company’s stock valued at $589,000 after purchasing an additional 24,130 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Viking Therapeutics during the 4th quarter valued at approximately $429,000. LPL Financial LLC increased its position in Viking Therapeutics by 18.2% during the 4th quarter. LPL Financial LLC now owns 96,702 shares of the biotechnology company’s stock valued at $3,891,000 after purchasing an additional 14,873 shares during the period. Finally, Concurrent Investment Advisors LLC acquired a new stake in Viking Therapeutics during the 1st quarter valued at approximately $220,000. Institutional investors and hedge funds own 76.03% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.